Francis Medical launches commercial Vanquish procedures for prostate tissue ablation. Explore what this means for minimally invasive prostate cancer treatment.
Bayer’s lawsuit against Johnson and Johnson raises critical questions about real-world evidence and oncology marketing. Read what this means for drug claims.
GT Biopharma's GTB-5550 gets FDA clearance for a Phase 1 solid tumor trial. Find out how this NK cell engager could reshape B7-H3 cancer immunotherapy.
Doctors Studio’s ozone pilot shows promising 30-day shifts in prostate biomarkers tracked via EpiSwitch PSE. Could this reshape trial design? Find out.
The recent FDA approval of Rubraca (rucaparib) for pre-chemotherapy use in BRCA-mutated metastatic castration-resistant prostate cancer marks a strategic inflection for the field. This expanded indication, driven by head-to-head superiority over docetaxel in the TRITON3 Phase 3 trial, positions BRCA mutations as the first molecular biomarker in prostate cancer to carry actionable, label-defining weight in
The class of poly (ADP-ribose) polymerase inhibitors, once celebrated as a breakthrough in ovarian and breast cancer, has endured a reputation decline following safety concerns and regulatory rollbacks. But recent data suggest that prostate cancer, specifically metastatic castration-resistant prostate cancer with BRCA mutations, may offer PARP inhibitors a new lease on life. The December 2025